Volume 2 Supplement 1

2005 International Meeting of The Institute of Human Virology

Open Access

Can Vaccine-induced Mucosal High Avidity CD8+ CTL Delay AIDS-viral Dissemination from Mucosa?

  • Igor M Belyakov1,
  • Vladimir A Kuznetsov2,
  • Brian Kelsall3,
  • Dennis Klinman4,
  • Marcin Moniuszko1,
  • Michael Lemon1,
  • Phillip D Markham5,
  • Ranajit Pal5,
  • John D Clements6,
  • Mark G Lewis7,
  • Warren Strober3,
  • Genoveffa Franchini1 and
  • Jay A Berzofsky1Email author
Retrovirology20052(Suppl 1):S100

DOI: 10.1186/1742-4690-2-S1-S100

Published: 8 December 2005

Natural HIV transmission occurs through mucosa, but it is debated whether mucosal cytotoxic T lymphocytes (CTL) can prevent or reduce dissemination from the initial mucosal site to the systemic circulation. Also, the role of CTL avidity in mucosal AIDS viral transmission is unknown. To address these questions, we used delay in acute-phase peak viremia after intrarectal challenge as an indicator of systemic dissemination. We find that a peptide-prime/poxviral boost vaccine inducing high levels of high avidity mucosal CTL can impact dissemination of intrarectally administered pathogenic SHIV-ku2 in macaques, and that such protection correlates better with mucosal than with systemic CTL and particularly with levels of high avidity mucosal CTL.

Notes

Authors’ Affiliations

(1)
Vaccine Branch, NCI, NIAID, NIH
(2)
Division of Information and Mathematical Sciences, Genome Institute of Singapore
(3)
Laboratory Of Clinical Investigation, NIAID, NIH
(4)
Center for Biologics Evaluation and Research, Food and Drug Administration
(5)
Advanced BioScience Laboratories, Inc.
(6)
Department of Microbiology and Immunology, Tulane University School of Medicine
(7)
Southern Research Institute

Copyright

© The Author(s) 2005

Advertisement